← Leaderboards
Michael G. Ziegler
University Of California San Diego
$7,592,003
Attributed
$7,592,003
Total exposure
14
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $650.8K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$7,592,003 · 14
By mechanism
P01$3,653,465 · 3
U09$3,205,009 · 1
M01$414,902 · 9
U01$318,627 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Daniel T O'Connor$5,574,664
- Vivian Y. H. Hook$23,603,887
- Xuping Bao$652,860
- Laurent Taupenot$1,672,200
- Christopher Rogers$5,223,901
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationIrbesartanBlood PressureEssential HypertensionAngiotensin ReceptorEpinephrineCardiovascular Disorder ChemotherapyDiabetic NephropathyNoninsulin Dependent Diabetes MellitusDrug Adverse EffectExtraterrestrial EnvironmentDrug Screening /EvaluationGravityHormone ReceptorCreatinineDeathDrug ToleranceEnvironmental AdaptationBlood ChemistryChronic Disease /DisorderAngiotensin IiBaroreflex
Grant awards (83)
Core--Biochemistry and Signal Transduction$241,145
P01 · FY2009 · HL · contact PI
Catecholamine biosynthesis and blood pressure$241,144
P01 · FY2009 · HL · contact PI
Catecholamine biosynthesis and blood pressure$290,964
P01 · FY2008 · HL · contact PI
Core--Biochemistry and Signal Transduction$164,587
P01 · FY2008 · HL · contact PI
Catecholamine biosynthesis and blood pressure$305,839
P01 · FY2007 · HL · contact PI
Core--Biochemistry and Signal Transduction$172,875
P01 · FY2007 · HL · contact PI
BLOOD PRESSURE CONTROL$14,729
M01 · FY2007 · RR · contact PI
Catecholamine biosynthesis and blood pressure$293,214
P01 · FY2006 · HL · contact PI
Core--Biochemistry and Signal Transduction$165,619
P01 · FY2006 · HL · contact PI
BLOOD PRESSURE CONTROL$88,818
M01 · FY2006 · RR · contact PI
Catecholamine biosynthesis and blood pressure$284,823
P01 · FY2005 · HL
Core--Biochemistry and Signal Transduction$160,859
P01 · FY2005 · HL
EPHEDRA AMPHETAMINE CROSS REACTIONS$156,296
M01 · FY2005 · RR
BLOOD PRESSURE CONTROL$48,843
M01 · FY2005 · RR
Blood Pressure Control$106,216
M01 · FY2004 · RR
SCIENTIFIC REVIEW AND EVALUATION AWARD NCRR REV CMTES$1,705,009
U09 · FY2002 · RR
Phenotyping--vasoactive post synaptic agonist pharmacog$318,627
U01 · FY2002 · HL
EXTRA ADRENAL EPINEPHRINE$159,403
P01 · FY2002 · HL
CORE--BIOCHEMISTRY$159,403
P01 · FY2002 · HL
CORE--BIOCHEMISTRY$159,403
P01 · FY2002 · HL
EXTRA ADRENAL EPINEPHRINE$159,403
P01 · FY2002 · HL
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2002 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2002 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2002 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2002 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2002 · RR
BAROREFLEX TESTING$0
M01 · FY2002 · RR
BAROREFLEX TESTING$0
M01 · FY2002 · RR
BAROREFLEX TESTING$0
M01 · FY2002 · RR
BAROREFLEX TESTING$0
M01 · FY2002 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2002 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2002 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2002 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2002 · RR
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2002 · RR
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2002 · RR
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2002 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2002 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2002 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2002 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2002 · RR
NOX-100 FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION$0
M01 · FY2002 · RR
NOX-100 FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION$0
M01 · FY2002 · RR
NOX-100 FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION$0
M01 · FY2002 · RR
NOX-100 FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION$0
M01 · FY2002 · RR
Phenotyping--vasoactive post synaptic agonist pharmacog$0
U01 · FY2002 · HL
SCIENTIFIC REVIEW AND EVALUATION AWARD NCRR REV CMTES$1,200,000
U09 · FY2001 · RR
CORE--BIOCHEMISTRY$159,403
P01 · FY2001 · HL
EXTRA ADRENAL EPINEPHRINE$159,403
P01 · FY2001 · HL
Phenotyping--vasoactive post synaptic agonist pharmacog$0
U01 · FY2001 · HL
Phenotyping--vasoactive post synaptic agonist pharmacog$0
U01 · FY2001 · HL
BAROREFLEX TESTING$0
M01 · FY2001 · RR
BAROREFLEX TESTING$0
M01 · FY2001 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2001 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2001 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2001 · RR
NOX-100 FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION$0
M01 · FY2001 · RR
NOX-100 FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION$0
M01 · FY2001 · RR
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2001 · RR
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2001 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2001 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2001 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2001 · RR
SCIENTIFIC REVIEW AND EVALUATION AWARD NCRR REV CMTES$300,000
U09 · FY2000 · RR
CORE--BIOCHEMISTRY$187,989
P01 · FY2000 · HL
EXTRA ADRENAL EPINEPHRINE$187,989
P01 · FY2000 · HL
NOX-100 FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION$0
M01 · FY2000 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2000 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2000 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT &AMLODIPINE$0
M01 · FY2000 · RR
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2000 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2000 · RR
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2000 · RR
LOSARTAN IN MILD TO MODERATE ESSENTIAL HYPERTENSION$0
M01 · FY2000 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2000 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2000 · RR
POST SPACEFLIGHT ORTHOSTATIC INTOLERANCE$0
M01 · FY2000 · RR
BAROREFLEX TESTING$0
M01 · FY2000 · RR
BAROREFLEX TESTING$0
M01 · FY2000 · RR
BAROREFLEX TESTING$0
M01 · FY2000 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2000 · RR
THE EFFECT OF IRBESARTAN ON TYPE II DIABETES$0
M01 · FY2000 · RR
NOX-100 FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION$0
M01 · FY2000 · RR